Cargando…

Efficacy and Safety of Fingolimod in an Unselected Patient Population

BACKGROUND: Fingolimod is a first in class oral compound approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS). The aim of this study was to evaluate clinical and neuroradiological responses to fingolimod as well as the safety and tolerability in RR-MS patients in clinical pra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rasenack, Maria, Rychen, Jonathan, Andelova, Michaela, Naegelin, Yvonne, Stippich, Christoph, Kappos, Ludwig, Lindberg, Raija L. P., Sprenger, Till, Derfuss, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703383/ https://www.ncbi.nlm.nih.gov/pubmed/26734938 http://dx.doi.org/10.1371/journal.pone.0146190

Ejemplares similares

Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis
por: Weier, Katrin, et al.
Publicado: (2014)

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
por: Meira, Maria, et al.
Publicado: (2014)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study
por: Magon, Stefano, et al.
Publicado: (2014)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
por: Zimmermann, Maria, et al.
Publicado: (2015)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST)
por: Amann, Michael, et al.
Publicado: (2014)

Fingolimod in children with Rett syndrome: the FINGORETT study
por: Naegelin, Yvonne, et al.
Publicado: (2021)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

Lymphocyte recovery after fingolimod discontinuation in patients with MS
por: Nagy, Sara, et al.
Publicado: (2020)

PARP-1 deregulation in multiple sclerosis
por: Meira, Maria, et al.
Publicado: (2019)

Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis
por: Cerdá-Fuertes, Nuria, et al.
Publicado: (2023)

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS
por: Mehling, Matthias, et al.
Publicado: (2014)

Longitudinal patterns of cortical thinning in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2020)

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2017)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients
por: Parmar, Katrin, et al.
Publicado: (2021)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Brain atrophy measurement over a MRI scanner change in multiple sclerosis
por: Sinnecker, Tim, et al.
Publicado: (2022)

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
por: Cohen, Jeffrey A., et al.
Publicado: (2019)

Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis
por: Cerdá-Fuertes, Nuria, et al.
Publicado: (2023)

Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study
por: Woelfle, Tim, et al.
Publicado: (2021)

Longitudinal changes of deep gray matter shape in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2022)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice
por: Fonseca, Joaquim
Publicado: (2015)

Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum
por: Naegelin, Yvonne, et al.
Publicado: (2018)

Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective
por: Woelfle, Tim, et al.
Publicado: (2023)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Yavari, Fatemeh, et al.
Publicado: (2021)

Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021)

Neurological safety of fingolimod: An updated review
por: Yoshii, Fumihito, et al.
Publicado: (2017)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance
por: Tsagkas, Charidimos, et al.
Publicado: (2021)

Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis
por: Cagol, Alessandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_odlmo2p0bqil7ohmi505l0p0j5